What top creators are saying about Regeneron Pharmaceuticals Inc.(REGN)
Biotechnology company that develops medicines for serious medical conditions.
10 AI-extracted insights from 4 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 2 scored insights about Regeneron Pharmaceuticals Inc..
The Take
Coverage of Regeneron Pharmaceuticals (REGN) was sparse and mostly neutral: one source briefly expressed bullishness without giving a catalyst, while the other mentions offered little company-specific analysis. One post noted the stock was down 21% since July 1.
Bull Case
- Positive sentiment: One speaker briefly said they were bullish on Regeneron but did not explain why (per The Shkreli Pill).
Bear Case
- Recent performance: A post reported REGN was down 21% since July 1, without offering a company-specific thesis (per Martin Shkreli).
Catalysts & Targets
- October 12, 2026 post: reported a 21% decline since July 1.
AI-generated summary. Not investment advice. Learn more.
Top creators covering Regeneron Pharmaceuticals Inc. (REGN)
The 4 sources with the most insights about Regeneron Pharmaceuticals Inc. on Kazuha.
Latest insights about Regeneron Pharmaceuticals Inc. (REGN)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Wednesday, November 4, 2026
Regeneron was mentioned in connection with a Huntington's disease treatment program, with no view on the stock or investment potential.
Monday, October 12, 2026
Described as moving only slightly during a generally quiet pharmaceutical session; no company-specific thesis was offered.
Friday, October 2, 2026
The speaker briefly said he was bullish on Regeneron, without explaining the catalyst.
Wednesday, September 30, 2026
Regeneron was mentioned without meaningful analysis or an investment view.
Saturday, September 26, 2026
Eylea was cited as the established comparator that Kodiak's drug had not convincingly surpassed.
Sunday, May 3, 2026
Included in the list of potential candidates for capital deployment.
Wednesday, November 19, 2025
The stock was briefly halted for news related to its '8mg' product, but the event was dismissed as being 'no big deal' and insignificant.
Friday, August 29, 2025
Stock is down 19% due to underperformance in the pharma sector caused by political pressure to lower U.S. drug prices.
Monday, July 14, 2025
Listed as one of the biotech/pharma companies the speaker holds positive views on and/or has positions in.
Thursday, July 10, 2025
The speaker expressed a brief, slightly bullish sentiment: 'I like Regeneron, yeah.'
Wednesday, November 4, 2026
Regeneron was mentioned in connection with a Huntington's disease treatment program, with no view on the stock or investment potential.
Monday, October 12, 2026
Described as moving only slightly during a generally quiet pharmaceutical session; no company-specific thesis was offered.
Friday, October 2, 2026
The speaker briefly said he was bullish on Regeneron, without explaining the catalyst.
Wednesday, September 30, 2026
Regeneron was mentioned without meaningful analysis or an investment view.
Saturday, September 26, 2026
Eylea was cited as the established comparator that Kodiak's drug had not convincingly surpassed.
Sunday, May 3, 2026
Included in the list of potential candidates for capital deployment.
Wednesday, November 19, 2025
The stock was briefly halted for news related to its '8mg' product, but the event was dismissed as being 'no big deal' and insignificant.
Friday, August 29, 2025
Stock is down 19% due to underperformance in the pharma sector caused by political pressure to lower U.S. drug prices.
Monday, July 14, 2025
Listed as one of the biotech/pharma companies the speaker holds positive views on and/or has positions in.
Thursday, July 10, 2025
The speaker expressed a brief, slightly bullish sentiment: 'I like Regeneron, yeah.'
Discussed alongside Regeneron Pharmaceuticals Inc. (REGN)
Other assets that creators frequently mention in the same content as Regeneron Pharmaceuticals Inc..
Frequently asked
Which podcasters and creators cover Regeneron Pharmaceuticals Inc. (REGN) the most?
The most active sources covering Regeneron Pharmaceuticals Inc. (REGN) on Kazuha are @realmartinshkreli, @theshkrelipill, amitisinvesting, Steve Eisman. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Regeneron Pharmaceuticals Inc. (REGN) are on Kazuha?
Kazuha has indexed 10 AI-extracted insights about Regeneron Pharmaceuticals Inc. (REGN) from 4 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Regeneron Pharmaceuticals Inc. (REGN)?
Creators covering Regeneron Pharmaceuticals Inc. (REGN) most frequently also discuss INTC, NVDA, MRNA, AMD, SNDK. See the "Discussed alongside" section above for full asset pages.